Biodistribution of doxorubicin-alkylated poly(l-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration

European Journal of Pharmaceutical Sciences

Volumn 31, Issue 1, 2007, Pages 43-52

  Colombo, Pierre Emmanuel ^a   Boustta, Mahfoud ^b   Poujol, Sylvain ^a   Pinguet, Frédéric ^a   Rouanet, Philippe ^a   Bressolle, Françoise ^a,b   Vert, Michel ^c  

^a Anticancer Center   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Antitumoral; Doxorubicin; Drug delivery systems; Macromolecular prodrug; Peritoneal carcinomatosis; Poly(l lysine citramide imide); Polymer therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICIN POLYLYSINE CITRAMID IMIDE CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PERITONEAL FLUID LEVEL; DRUG RETENTION; DRUG TISSUE LEVEL; NONHUMAN; PERITONEUM CANCER; PERITONITIS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; ASCITIC FLUID; CARCINOMA; CELL LINE, TUMOR; DOXORUBICIN; MALE; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; NYLONS; PERITONEAL NEOPLASMS; PERITONITIS; RATS; RATS, INBRED STRAINS;

EID: 34247223583     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.02.004     Document Type: Article

References (31)

1. Abdellaoui K., Boustta M., Vert M., Morjani H., and Manfait M. Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bioresorption. Eur. J. Pharm. Sci. 6 (1998) 61-73
2. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., Franklin E.W., Clarke-Pearson D.L., Malviya V.K., DuBeshter B., Adelson M.D., and Hoskins W.J. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
3. Araki H., Tani T., and Kodama M. Antitumor effect of cisplatin incorporated into polylactic acid microcapsules. Artif. Organs 23 (1999) 161-168
4. Armstrong D.K., Bundy B.N., Baergen R., Lele S.B., Copeland L.J., Walker J., and Burger R. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Pro. Am. Soc. Clin. Oncol. (2002) (abstract 803)
5. Balthasar J.P., and Fung H.L. Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Life Sci. 58 (1996) 535-543
6. Benoit L., Duvillard C., Beltramo J.L., Brunet-Lecomte P., and Chauffert B. Intraperitoneal cisplatin plus epinephrine and surgical debulking for the treatment of advanced peritoneal carcinomatosis in the rat. Gastroenterol. Clin. Biol. 24 (2000) 26-30
7. Boustta M., Huguet J., and Vert M. New functional polyamides derived from citric acid and l-lysine: synthesis and characterization. Macromol. Chem., Macromol. Symp. 47 (1991) 345-355
8. Chauffert B., Dimanche-Boitrel M.T., Genne P., Petit J.M., Onier N., and Jeannin J.F. Experimental chemotherapy of peritoneal carcinomatosis of colonic origin in rats. Gastroenterol. Clin. Biol. 16 (1992) 215-219
9. Couffin-Hoarau A.C., Boustta M., and Vert M. Enlarging the library of poly(l-lysine citramide) polyelectrolytic drug carriers. J. Polym. Sci. Pt. A: Polym. Chem. 39 (2001) 3475-3484
10. Configliacchi E., Razzano G., Rizzo V., and Vigevani A. HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates. J. Pharm. Biomed. Anal. 15 (1996) 123-129
11. Dedrick R.L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. 12 (1985) 1-6
12. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?. Pharm. Sci. Technol. Today 2 (1999) 441-449
13. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., and Searle F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release 74 (2001) 135-146
14. Farenc C., Fabreguette J.R., and Bressolle F. Pk fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput. Biomed. Res. 33 (2000) 315-330
15. Fraier D., Frigerio E., Pianezzola E., Strolin B.M., Cassidy J., and Vasey P. A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection. J. Pharm. Biomed. Anal. 13 (1995) 625-633
16. Gautier S., Boustta M., and Vert M. Alkylated poly(l-lysine citramide) as models to investigate the ability of amphiphilic macromolecular drug carriers to physically entrap lipophilic compounds in aqueous media. J. Control. Release 60 (1999) 235-247
17. Jacquet P., Averbach A., Stuart O.A., Chang D., and Sugarbaker P.H. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother. Pharmacol. 41 (1998) 147-154
18. Kovar M., Mrkvan T., Strohalm J., Etrych T., Ulbrich K., Stastny M., and Rihova B. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. J. Control. Release 92 (2003) 315-330
19. Li C. Poly(l-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 54 (2002) 695-713
20. Luftensteiner C.P., Schwendenwein I., Paul B., Eichler H.G., and Viernstein H. Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats. J. Control. Release 57 (1999) 35-44
21. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
22. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 4 (2003) 277-283
23. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., Wadler S., and Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
24. Poujol S., Pinguet F., Bressole F., Boustta M., and Vert M. Molecular microencapsulation: paclitaxel formulations in aqueous medium using hydrophobized poly(l-lysine citramide imide). J. Bioact. Compat. Polym. 15 (2000) 99-114
25. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci.: Polym. Sym (1975) 135-153
26. Rossi C.R., Mocellin S., Pilati P., Foletto M., Quintieri L., Palatini P., and Lise M. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg. Oncol. Clin. N. Am. 12 (2003) 781-794
27. Shiah J.J., Sun Y., Peterson C.M., and Kopecek J. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J. Control. Release 61 (1999) 145-157
28. Sugarbaker P.H., Mora J.T., Carmignani P., Stuart O.A., and Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10 (2005) 112-122
29. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5 (1999) 83-94
30. Vert M. Polyvalent polymeric drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 2 (1986) 291-327
31. Verwaal V.J., van Ruth S., de Bree E., van Slooten G.W., van Tinteren H., Boot H., and Zoetmulder F.A.N. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21 (2003) 3737-3743